891 resultados para imunomodulação humoral


Relevância:

10.00% 10.00%

Publicador:

Resumo:

Chromoblastomycosis (CBM) is a chronic subcutaneous infection caused by several dematiaceous fungi. The most commonly etiological agent found in Brazil is Fonsecaea pedrosoi, which appears as thick walled, brownish colored cells with transverse and longitudinal division in the lesions, called "muriform cells". This disease is found worldwide but countries like Madagascar and Brazil have highest incidence. Diagnosis is made by clinical, direct and histopathologic examination and culture of specimens. Serological tests have been used to identify specific antibodies against Fonsecaea pedrosoi antigens, as well as immunotechniques have been used for CBM serological identification and diagnosis. In the present study double immunodiffusion (DID), counterimmunoelectrophoresis (CIE) and immunoenzymatic test (ELISA) have been used to evaluate humoral immune response in patients with CBM caused by F. pedrosoi. Metabolic antigen was used for immunoprecipitation tests (DID and CIE) while somatic antigen for ELISA. Our results demonstrated 53% sensitivity and 96% specificity for DID, while CIE presented 68% sensitivity and 90.5% specificity. ELISA demonstrated 78% sensibility and 83% specificity. Serological tests can be a useful tool to study different aspects of CBM, such as helping differential diagnosis, when culture of the pathogenic agent is impossible.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

O aparecimento recente do sarcoma de Kaposi (SK)epidémico na prática clínica corrente da Medicina Interna veio permitir encontrar expressões clínicas raras, como a pulmonar (SKP). A radiologia tem um papel preponderante na avaliação da extensão do SKP. A grande agressividade que por vezes apresenta conduziu à investigação de novas terapêuticas em diferentes áreas (imunomodulação, hormonal e citostática). Os novos conceitos quanto à sua provável origem talvez permitam que, a curto prazo, seja mais uma profilaxia nos imunodeprimidos pelo VIH.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Aim: To characterise clinically the patients with C4d in peritubular capillaries deposits (C4dPTCD) and/or circulating anti-HLA class I/II alloantibodies. To determine the correlation between positive C4dPTCD and circulating anti-HLA class I/II alloantibodies during episodes of graft dysfunction. Subjects and Methods: C4d staining was performed in biopsies with available frozen tissue obtained between January 2004 and December 2006. The study was prospective from March 2005, when a serum sample was obtained at the time of biopsy to detect circulating anti-HLA class I/II alloantibodies. Results: We studied 109 biopsies in 86 cadaver renal transplant patients. Sixteen of these (14.7%) presented diffuse positive C4dPTCD. There was a 13.5% rate of +C4dPTCD incidence within the first six months of transplantation and 16% after six months (p>0.05). Half of the +C4dPTCD in the first six months was associated with acute humoral rejection. After six months, the majority of +C4dPTCD (n=7/8) was present in biopsies with evidence of interstitial fibrosis/tubular atrophy and/or transplant glomerulopathy. The C4dPTCD was more frequent in patients with positive anti-HCV antibodies(p<0.0001), a previous renal transplant (p=0.007), and with a panel reactivity antibody (PRA) ≥ 50%(p=0.0098). The anti-HCV+ patients had longer time on dialysis (p=0.0019) and higher PRA(p=0.005). Circulating anti-HLA I/II alloantibodies were screened in 46 serum samples. They were positive in 10.9% of samples, all obtained after six months post transplant. Circulating alloantibodies were absent in 92.5% of the C4d negative biopsies. Conclusion: We found an association between the presence of C4dPTCD and 2nd transplant recipients,higher PRA and the presence of anti-HCV antibodies. The presence of HCV antibodies is not a risk factor for C4dPTCD per se, but appears to reflect longer time on dialysis and presensitisation. In renal dysfunction a negative alloantibody screening is associated with a reduced risk of C4dPTCD (<10%).

Relevância:

10.00% 10.00%

Publicador:

Resumo:

INTRODUCTION: ABO-incompatible liver transplantation (ABOi LT) is considered to be a rescue option in emergency transplantation. Herein, we have reported our experience with ABOi LT including long-term survival and major complications in these situations. PATIENT AND METHODS: ABOi LT was performed in cases of severe hepatic failure with imminent death. The standard immunosuppression consisted of basiliximab, corticosteroids, tacrolimus, and mycophenolate mofetil. Pretransplantation patients with anti-ABO titers above 16 underwent plasmapheresis. If the titer was above 128, intravenous immunoglobulin (IVIG) was added at the end of plasmapheresis. The therapeutic approach was based on the clinical situation, hepatic function, and titer evolution. A rapid increase in titer required five consecutive plasmapheresis sessions followed by administration of IVIG, and at the end of the fifth session, rituximab. RESULTS: From January 2009 to July 2012, 10 patients, including 4 men and 6 women of mean age 47.8 years (range, 29 to 64 years), underwent ABOi LT. At a mean follow-up of 19.6 months (range, 2 days to 39 months), 5 patients are alive including 4 with their original grafts. One patient was retransplanted at 9 months. Major complications were infections, which were responsible for 3 deaths due to multiorgan septic failure (2 during the first month); rejection episodes (4 biopsy-proven of humoral rejections in 3 patients and 1 cellular rejection) and biliary. CONCLUSION: The use of ABOi LT as a life-saving procedure is justifiable in emergencies when no other donor is available. With careful recipient selection close monitoring of hemagglutinins and specific immunosuppression we have obtained acceptable outcomes.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

The immune response expressed by IgG antibodies in BALB/c mice experimentally infected with Toxocara canis, was studied with the aim of verifying the possible in vivo cross-reactivity between antigens of T. canis and other parasites (Ascaris suum, Taenia crassiceps, Schistosoma mansoni, Strongyloides venezuelensis and Toxoplasma gondii). Experiments included three groups of mice: one infected only by T. canis, another with one of the other species of parasites and a third concomitantly infected with T. canis and the other species in question. Animals were bled by orbital plexus at 23, 38 and 70 days post infection (p.i.). Sera were analyzed for anti-Toxocara antibodies by ELISA and Immunoblotting, using excretion-secretion antigens (ES), obtained from culture of third-stage larvae of T. canis. For all experiments a control group comprised by ten non-infected mice was used. Only in the case of A. suum infection, in these experimental conditions, the occurrence of cross-reactivity with T. canis was observed. However, in the case of co-infection of T. canis - S. mansoni, T. canis - S. venezuelensis and T. canis - T. crassiceps the production of anti-Toxocara antibodies was found at levels significantly lower than those found in mice infected with T. canis only. Co-infection with S. mansoni or S. venezuelensis showed lower mortality rates compared to what occurred in the animals with single infections. Results obtained in mice infected with T. canis and T. gondii showed significant differences between the mean levels of the optical densities of animals infected with T. canis and concomitantly infected with the protozoan only in the 23rd day p.i.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Toxoplasmosis is frequently acquired through the oral route by the ingestion of cysts or oocysts of Toxoplasma gondii. Once ingested, the parasites penetrate the intestinal epithelial cells and rapidly disseminate to all organs in the host. During T. gondii infection, the intestinal microbiota plays an important role in stimulating a protective immune response against the parasite. In this sense the use of probiotics is worthy of note since they are live microorganisms that have beneficial effects on the host through stimulation of the immune response that can be important in the control of T. gondii proliferation and dissemination in the host. In the present study, the action of the probiotic Bifidobacterium animalis subsp. lactis was investigated in C57BL/6 mice infected with oocysts of ME49 strain of T. gondii. The probiotic had an immunomodulatory action, inducing CD19 lymphocyte proliferation and consequently increasing anti-T. gondii antibody level.Bifidobacterium animalis subsp. lactisprovided protection in supplemented mice, compared to the control group. In addition, supplemented animals had milder inflammatory process in the small intestine, indicating that the probiotic protects the intestinal mucosa during infection with T. gondii. It was concluded that the probioticB. animalis subsp. lactis induces humoral immune response capable of providing protection against T. gondii infection.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

INTRODUCTION: With the introduction of combination antiretroviral therapy (cART), prognosis of human immunodeficiency virus (HIV) infection has been improved and kidney transplantation (KT) in HIV-positive patients became possible. METHODS: We reviewed the demographic, clinical, laboratory, and therapeutic data of all the HIV-infected patients who underwent KT between 2009 (first KT in Portugal in a HIV-infected patient) and May 2014. Case accrual was through all Portuguese KT centers where a KT in an HIV-infected patient was performed. Patients were transplanted following the American and Spanish guideline recommendations that included maintenance on cART, undetectable plasma HIV RNA copies, and absolute CD4 counts of ≥ 200 cells/μL in the last 6 months. RESULTS: Fourteen KT were performed on men and 3 on women. The mean age of patients at the time of transplantation was 49.9 ± 11.7 years. HIV status was known for 12 ± 5 years. Eight patients had AIDS in the past and all patients received grafts from deceased donors. Twelve patients (64.7%) underwent induction therapy with basiliximab and 2 patients experienced early graft loss. In 2 patients, humoral rejection was diagnosed and in 3 patients, cellular rejection. Two patients died and an additional patient had early graft loss. CONCLUSION: KT is a possible, but challenging, renal replacement therapy in selected HIV-positive patients. Even in those with AIDS criteria in the past, when the disease is controlled, and after the reconstitution of the immune system with cART, KT can be performed. Nevertheless, the risk-benefit ratio for each patient needs to be taken in consideration.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Coelhos inoculados com tripomastigotas da cepa Ernestina do Trypanosoma cruzi tiveram parasitemias, demonstradas pelo xenodiagnóstico, até cinco meses e meio após a infecção. O tratamento de alguns desses coelhos com benzonidazol, na dose de 8mg/kg durante sessenta dias, após dois meses de infecção, resultou na negativação dos xenos após 30 dias de uso da medicação. Os coelhos chagásicos crônicos, após seis meses de infecção, já tinham a parasitemia subpatente quando foram submetidos a tratamento idêntico àqueles da fase aguda. Em ambos os casos, os coelhos tratados com benzonidazol tiveram títulos de anticorpos humorais semelhantes àqueles verificados nos coelhos chagásicos não- tratados, inclusive durante a quimioterapia. A não alteração da imunidade humoral em coelhos tratados foi comprovada quando animais chagásicos e não chagásicos submetidos ao tratamento produziram títulos de anticorpos hemolíticos idênticos àqueles verificados nos animais não-tratados. Em acentuado contraste, a função imune timo-dependente foi severamente alterada pelo uso do benzonidazol. As reações de hipersensibilidade tardia contra um antígeno sub- celular do T. cruzi foram suprimidas durante a vigência do tratamento dos coelhos chagásicos. Paralelamente, estas reações eram intensas nos coelhos chagásicos não-tratados e negativas em coelhos controles normais. Todavia, as reações cutâneas tornaram-se novamente positivas 10 dias após o tratamento. Foi interessante notar que as reações de hipersensibilidade tardia in vivo, em coelhos imunizados com BCG e testados com PPD ou em coelhos sensibilizados com DNCB também foram suprimidas durante o tratamento com o benzonidazol. Contudo, as reações de imunidade celular contra estes antígenos também reverteram aos valores normais 7 a 10 dias após a suspensão do benzonidazol. Resultados semelhantes foram relatados em relação ao nifurtimox, outra droga utilizada no tratamento da doença de Chagas. 0 benzonidazol e o nifurtimox são compostos nitro-aromáticos cuja nitrorredução resulta na formação de metabólitos intermediários potencialmente citotóxicos para o protozoário e para as células do hospedeiro.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Acute otitis media (AOM) is the most common infection in childhood, resulting from both anatomic and immunologic specificities of this age group. Recurrent AOM has been defined as one of the warning signs for primary immunodeficiencies (PID), In this study we evaluated the strength of recurrent AOM as clinical predictor of PID. Methods: Retrospective study (August 2010 - December 2013) which included all patients referred to PID appointment because of recurrent AOM (= 8 AOM episodes/year). Syndromic patients or those presenting with another warning sign for PID were excluded. Clinical, demographic and laboratory results were analized and statistical analysis was made using SPSS 20. Results: Seventy-five patients were included (median age 37,8 months; 62,7% male gender), corresponding to 15% of all first appointments. Other comorbidities were present in 20% of the patients and 17% had ORL surgery prior to PID referral. In most patients, the immunologic screening consisted on the evaluation of humoral function, but in selected cases other studies were performed (namely complement and lymphocyte immunophenotyping). A PID was identified in 12 children (16,0%) and the majority of these patients had other distinctive feature (personal or familiar antecedent of infection or auto-immunity, 66,7%, p<0,05). Nine children (12,0%) underwent prophylactic cotrimoxazole. The average length of follow-up was 11,2 months. Conclusion: Despite being a very frequent cause of immunologic screening, in this study recurrent AOM was not found to be a good predictor of underlying PID, unless the patients presents other significant personal or family history.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

A fim de se observar uma possível proteção conferida pela infecção espúria contra uma infecção verdadeira por Capillaria hepatica, camundongos foram inoculados com ovos não embrionados (infecção espúria) e, posteriormente, com ovos embrionados (infecção verdadeira). Anticorpos específicos da classe IgG, detectados por teste imunoenzimático (ELISA), mostraram-se elevados a partir da segunda semana do experimento. O teste de hipersensibilidade cutânea tardia resultou negativo. O exame das lesões do fígado, assim como a contagem de ovos, utilizados como parâmetros para comparação entre os grupos de animais estudados, não apresentaram variação significativa indicando que a imunidade humoral induzida pela infecção espúria não tem potencial protetor.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

O vírus rábico RV194-2, uma variante avirulenta da cepa CVS (Challenge Vírus Standard), produz uma infecção inaparente quando inoculado intracerebralmente em camundongos adultos. Sugerindo que a resposta imunológica do hospedeiro permite a eliminação do vírus do sistema nervoso central. Por esta razão foram estudadas a indução de interferon e a resposta imune humoral em camundongos BALB/c inoculados com vírus RV194-2. Durante a infecção, estes camundongos apresentaram elevados níveis de interferon no plasma e no cérebro com altos títulos de anticorpos neutralizantes anti-rábicos. A 2-5A sintetase. um marcador da ação dos interferons,foi também analisada no cérebro destes animais. Sua atividade, aumentou, paralelamente, á produção de interferon, demonstrando que este interferon é bioquímicamente ativo. O vírus RV194-2 também induziu, 45 dias após sua inoculação, proteção aos animais quando desafiados com a cepa virulenta CVS. Estes resultados demonstram que a cepa RV194-2possui um alto nível imunogênico.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Humoral immune response using inactivated rabies vaccine was studied in 35 nelore cross-bred bovines of western region of São Paulo state. Ninety days after vaccination, 13 (92.8%) animals presented titers 30.5IU/ml, through mouse neutralization test. After 180 days, 9 (64.3%) sera showed titers 30.5IU/ml, after 270 days, only one (7.1%) showed a titer of 0.51IU/ml, and after 360 days, all animals showed titers < 0.5IU/ml. Group of animals receiving booster dose 30 days after vaccination presented, two months after, all with titers > 0.5IU/ml. At 180 days, 17 (80.9%) sera presented titers > 0.5IU/ml; at 270 days, 15 (71.4%), with titers 30.5IU/ml and at 360 days, 4 (19.0%), with titers 30.5IU/ml. Booster-dose ensured high levels of neutralizing antibodies for at least three months, and 240 days after revaccination, 71.4% of animals were found with titers 30.5IU/ml.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

A resposta imune humoral induzida pela vacina contra a raiva produzida em cérebros de camundongos recém-nascidos foi estudada em 23 cães e o teste de soroneutralização em camundongos foi usado para avaliação dos níveis de anticorpos rábicos. Um grupo com 10 animais recebeu vacina conservada de 2 a 8°C e apresentou os seguintes resultados: após 30 dias da vacinação 6 (60%) amostras responderam ao teste; após 180 dias 4 (40%) e após 360 dias apenas 1 (10%). O outro grupo com 13 cães recebeu vacina previamente congelada e somente 2 (15,4%) amostras no dia 30 apresentaram resposta satisfatória; os demais períodos (180 e 360) após a vacinação, não foi encontrado título. A análise estatística dos dados referentes a cada uma das variáveis consideradas no estudo foi efetuada segundo a técnica de análise de variância seguida por Tuckey e indicaram diferenças estatisticamente significativas entre os grupos.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Foram estudadas 48 crianças de 0 a 13 anos através da realização do ensaio imunoenzimático ligado a enzima (ELISA) para pesquisa de anticorpos da classe IgG antiPPD, visando estabelecer correlação entre a resposta imune humoral medida pela sorologia e a gravidade da tuberculose, segundo formas radiológicas (leve, moderada e grave). A amostra foi composta de 29 crianças com tuberculose e 19 sem tuberculose comunicantes de tuberculose). Os valores médios (medianas) da densidade óptica do teste ELISA foram, respectivamente: 0,098 na forma gânglio-pulmonar (leve), 0,092 na forma pneumônica (moderada) e 0,134 na tuberculose miliar (grave). Nas crianças não tuberculosas com radiografia de tórax normal, o ELISA foi igual a 0,020. Os achados evidenciam valores mais elevados do teste sorológico relacionados à maior gravidade da doença (p= 0,0007).

Relevância:

10.00% 10.00%

Publicador:

Resumo:

A hanseníase, cujo agente etiológico Mycobacterium Ieprae, é doença de amplo espectro clínico e imunopatológico. Suas apresentações clínicas estão correlacionadas com padrões imunológicos distintos, variando de uma vigorosa resposta imune mediada por células ao M. Ieprae, com padrão Th1 no pólo tuberculóide, a uma ausência de resposta celular específica aos antígenos do M. Ieprae no pólo lepromatoso, com predomínio da resposta Th2 e exacerbação da resposta humoral. É provável que a suscetibilidade ao M. Ieprae é determinada por diferentes genes polimórficos. Estudos adicionais são necessários para esclarecer os mecanismos das interações complexas entre as citocinas e a participação da diversidade fenotípica da rede de células que contribuem para a defesa do hospedeiro. O entendimento de tais mecanismos poderá oferecer novas abordagens para identificar agonistas e/ou antagonistas para os efeitos pró- ou anti-inflamatórios e em quais circunstâncias sua utilização seria apropriada para intervenções imunológicas e/ou imunoterapeuticas.